Parcourir Faculté de pharmacie – Travaux et publications par auteur·e "Marquis-Gravel, Guillaume"
Voici les éléments 1-3 de 3
-
Antiplatelet therapy for atherothrombotic disease in 2022 : from population to patient-centered approaches
Jourdi, Georges; Godier, Anne; Lordkipanidzé, Marie; Marquis-Gravel, Guillaume; Gaussem, Pascale (Frontiers Media, 2022-01-28)Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral ... -
Antiplatelet therapy in atherothrombotic diseases : similarities and differences across guidelines
Jourdi, Georges; Marquis-Gravel, Guillaume; Martin, Anne-Céline; Lordkipanidzé, Marie; Godier, Anne; Gaussem, Pascale (Frontiers media, 2022-04-27)Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases. Its use, especially in secondary cardiovascular prevention, has ... -
Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada
Lordkipanidzé, Marie; Marquis-Gravel, Guillaume; Tanguay, Jean-Francois; Mehta, Shamir R.; So, Derek Y. F. (Elsevier, 2020-12-16)Background The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary ...